Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open-Label Study to Evaluate Lazanda in Cancer Patients Receiving Palliative Radiation

NCT03071744 is registered in ClinicalTrials.gov with Joseph Ma as lead sponsor.

NCT NCT03071744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03071744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open-Label Study to Evaluate Lazanda in Cancer Patients Receiving Palliative Radiation
Lead sponsor
Joseph Ma
Phase
Phase 2
Overall status
Terminated
Start date
March 1, 2017
Completion date
March 9, 2018
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastases